retatrutide patent owner News: Lilly is fighting the FDA in court in an attempt to have the triple agonist peptide classified as a biologic. We broke down the potential strategy of Lilly on today’s podcast. Retatrutide—A Game Changer in Obesity
Description
Both have seen increased demand as patients and providers seek solutions beyond traditional pharma pipelines
The beneficial effects of SGLT2 inhibitors on metabolic outcomes (BP control, body weight) were also shown in a meta-analysis of RCTs in non-diabetic individuals [96]
Cheng H, Gang X, Liu Y, Wang G, Zhao X, Wang G
All approved forms require subcutaneous injection
